期刊文献+

核仁素在肿瘤发生发展中的作用 被引量:1

Role of nucleolin in the development of tumor
下载PDF
导出
摘要 核仁素是细胞核中一种高度保守的多功能蛋白,又称为C23,其在核仁中高度表达并参与多种生物学过程。近几年来,核仁素在肿瘤发生发展中的作用引起人们的广泛关注。核仁素通过作用多种致瘤基因(如Akt)间接或直接影响细胞周期促进细胞增殖,稳定抗凋亡因子IL-9和bcl-2等减少肿瘤细胞凋亡,激活自噬相关途径的基因诱发自噬。在肿瘤进展中,核仁素促进血管生成素的分泌活化内皮细胞(endothelial cells,EC),并且激活趋化因子信号通路提高肿瘤细胞的迁移和侵袭。近来适配子、多肽、免疫剂在核仁素治疗研究中取得了进展。核仁素作为独立预后标志物具有重要的价值。进一步探讨核仁素与肿瘤的关系以及肿瘤发生发展的分子机制,为肿瘤的治疗提供潜在的生物学作用靶点。 Nucleolin is a highly conservative multifunctional protein in the cell nucleus, also called C23, which is rich expressed in the nucleolus and participates in a variety of biological process. In recent years, the role of nucleolin in the development of tumor has received extensive attention. Nucleolin regulates a variety of tumorigenic gene(such as Akt) indirectly or directly influence cell cycle to promote cell proliferation, as well as stabilizes antiapoptotic factor IL-9 and bcl-2 reduced tumor cell apoptosis, activates the related gene in autophagy pathway induced autophagy. In tumor progression, nucleolin promotes the secretion of angiogenin and activates endothelial cells(EC), meanwhile activates chemokine signaling pathways to increase tumor cell migration and invasion. Recently, in the treatment of nucleolin, aptamer, polypeptide, and immunizing agent make a progress, and as an independent prognostic marker, nucleolin is of great value. Futher exploration on the relationship between nucleolin and tumor, as well as the molecular mechanism of tumor development helps provide potential biological targets for the treatment of tumor.
出处 《临床与病理杂志》 2017年第9期1954-1959,共6页 Journal of Clinical and Pathological Research
基金 国家自然科学基金(81501708)~~
关键词 核仁素 肿瘤 治疗 预后 nucleolin tumor treatment prognosis
  • 相关文献

参考文献1

二级参考文献13

  • 1Siegel R, MaJ, Zou Z, et al. Cancer Statistics, 2014 [J]. CA Cancer J Clin. 2014. 64 : 9-29.
  • 2Qiu W, Zhou F, Zhang Q, et al. Overexpression of nucleolin and different expression sites both related to the prognosis of gastric cancer [J]. AMPIS, 2013,121: 919-925.
  • 3Bates PJ, Laber DA, Miller DM, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer [J]. Exp Mol Pathol, 2009, 86: 151-164.
  • 4Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers [J]. Annu Rev Pharmacol Toxicol, 2010, 50: 237-257.
  • 5Soundararajan S, Wang L, Sridharan V, et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4- 11 leukemia cells [J]. Mol Pharmacol, 2009, 76: 984-991.
  • 6Mongelard F, Bouvet P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia [J]. Curr Opin Mol Ther, 2010, 12: 107-114.
  • 7Soundararajan S, Chen W, Spicer EK, et al. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells [J]. Cancer Res, 2008, 68: 2358- 2365.
  • 8Rosenberg JE, Bambury RM , Van Allen EM, et al. A phase n trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma [J]. Invest New Drugs, 2014, 32: 178-187.
  • 9Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised , placebo-controlled, multieentre study (lressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005, 366: 1527-1537.
  • 10Kelly K, Chansky K, Gaspar LE, et al. Phase Ⅲ Trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage Ⅲ non-small-cell lung cancer: SWOG 50023 [J]. J Clin Oncol, 2008, 26: 2450-2456.

共引文献4

同被引文献21

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部